Sutimlimab left 46 percent of trial patients without a hemoglobin response, yet two rival complement programs abandoned the disease after its launch.

Sutimlimab (Enjaymo) has been the only FDA-approved therapy for cold agglutinin disease since its February 2022 approval, an intravenous anti-C1s inhibitor dosed every two weeks for life. Its own pivotal CARDINAL trial found that 54 percent of patients met the composite hemoglobin-response endpoint, meaning 46 percent did not; responders gained a mean 2.6 g/dL in hemoglobin and 71 percent avoided transfusion between weeks 5 and 26. The trial leaves nearly half the treated population, and every patient's indefinite dosing burden, unresolved.

Cold agglutinin disease affects an estimated 5,000 patients in the US. Sutimlimab's list price implies annual treatment cost of roughly $259,000 to $302,000 per patient, and a Yale-led cost-effectiveness analysis put its incremental cost per QALY at $2.34 million against a $150,000 willingness-to-pay threshold, with standard of care favored in all 10,000 sensitivity iterations tested. No formal ICER review of sutimlimab has been published to date. A second entrant should expect payers to demand outcomes-based contracting or a materially lower net price before granting parity access.

Half the treated population still lacks a response, and no rival has filled the gap.

Five questions this report answers:

Q1 - Where exactly does sutimlimab's efficacy stop, and who is the 46 percent non-responder?

Q2 - Why did pegcetacoplan and iptacopan abandon cold agglutinin disease after sutimlimab's launch?

Q3 - What price and evidence package would US payers require from a second CAD therapy?

Q4 - What primary FDA and payer sources back every claim in this launch-readiness assessment?

Q5 - What does the CASCADE trial discontinuation imply for a new entrant's achievable trial population?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ColdAgglutininDisease #RareDisease #LaunchReadiness #USHealthcare #ComplementInhibitors

Live report page:  https://axlrx.ai/cold-agglutinin-disease/us/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/